Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Catalyst Biosciences, Inc. (CBIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.5100-0.0400 (-2.58%)
At close: 04:00PM EDT
1.4900 -0.02 (-1.32%)
After hours: 07:17PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.5500
Open1.5500
Bid1.5000 x 3100
Ask1.5200 x 1800
Day's Range1.4820 - 1.5800
52 Week Range0.3500 - 5.2000
Volume648,610
Avg. Volume6,041,030
Market Cap47.429M
Beta (5Y Monthly)1.97
PE Ratio (TTM)N/A
EPS (TTM)-3.0550
Earnings DateMar 02, 2022 - Mar 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateAug 20, 2015
1y Target Est11.33
  • American City Business Journals

    The Petri Dish: NIH gives $68M to Pfizer-partnered AI startup

    A roindup of companies developing drugs and devices, inking new partnership deals, raising money, expanding facilities and more.

  • Benzinga

    Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex

    Catalyst Biosciences Inc (NASDAQ: CBIO) has agreed to sell its portfolio of protease medicines that regulate complement to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) for $60 million. "This sale is part of the ongoing strategic process that we announced in February to explore alternatives and create value for shareholders. We have significantly reduced our cash burn and continue to work with our advisors to evaluate additional strategic alternatives for Catalyst," said Nassim Usman, CEO o

  • GlobeNewswire

    Catalyst Biosciences Sells Complement Portfolio for $60 Million

    SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it has signed a definitive asset purchase and sale agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) under which Vertex has acquired Catalyst’s portfolio of protease medicines that regulate complement, including CB 2782-PEG, for $60 million in cash. Management Comments“We have been exploring strategic alternatives to monetize our assets and maximize value f

Advertisement
Advertisement